Willingness-to-pay and parametric trends in cost-effectiveness and cost-utility studies in ophthalmology.

IF 2 Q2 OPHTHALMOLOGY
Aswen Sriranganathan, Rafael N Miranda, Tina Felfeli
{"title":"Willingness-to-pay and parametric trends in cost-effectiveness and cost-utility studies in ophthalmology.","authors":"Aswen Sriranganathan, Rafael N Miranda, Tina Felfeli","doi":"10.1136/bmjophth-2025-002279","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the frequencies of input parameters in cost-effectiveness analyses (CEA) within ophthalmology, particularly in willingness-to-pay (WTP), and to assess trends over time in studies conducted in the United States.</p><p><strong>Methods and analysis: </strong>A cross-sectional analysis of CEAs from the Tufts Medical Center CEA Registry spanning 1993 to 2022 was conducted, including all studies evaluating diseases of the eye and adnexa. The primary outcomes measured included trends in WTP thresholds, funding sources, types of interventions and disease classifications.</p><p><strong>Results: </strong>A total of 82 US-based CEAs met the inclusion criteria. All studies assessed outcomes in quality-adjusted life years (QALYs). WTP thresholds of US$50 000 (41%) and US$100 000 (39%) were most frequently reported, with US$150 000 emerging in 9% of studies since 2019. Discounting at 3.0% for costs and QALYs was universally applied. Government (33%), nonprofit (29%) and pharmaceutical (17%) funding predominated. Pharmaceutical-funded studies often employed higher WTP thresholds of US$100 000 (29%) and US$150 000 (29%). The most common intervention types were surgical (40%) and pharmaceutical (40%), whereas diseases of the choroid and retina (43%) were most frequently studied. Healthcare perspectives (17 studies) were more commonly reported than societal perspectives (6 studies).</p><p><strong>Conclusions: </strong>US-based ophthalmology CEAs commonly use US$50 000-$100 000 WTP thresholds and a 3.0% discount rate, with higher thresholds emerging recently. Public and nonprofit funding predominates, focusing on retinal diseases and surgical or pharmaceutical interventions. Reassessing fixed WTP thresholds and incorporating societal perspectives could improve CEAs' relevance, ensuring alignment with evolving economic and healthcare landscapes.</p>","PeriodicalId":9286,"journal":{"name":"BMJ Open Ophthalmology","volume":"10 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258325/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjophth-2025-002279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the frequencies of input parameters in cost-effectiveness analyses (CEA) within ophthalmology, particularly in willingness-to-pay (WTP), and to assess trends over time in studies conducted in the United States.

Methods and analysis: A cross-sectional analysis of CEAs from the Tufts Medical Center CEA Registry spanning 1993 to 2022 was conducted, including all studies evaluating diseases of the eye and adnexa. The primary outcomes measured included trends in WTP thresholds, funding sources, types of interventions and disease classifications.

Results: A total of 82 US-based CEAs met the inclusion criteria. All studies assessed outcomes in quality-adjusted life years (QALYs). WTP thresholds of US$50 000 (41%) and US$100 000 (39%) were most frequently reported, with US$150 000 emerging in 9% of studies since 2019. Discounting at 3.0% for costs and QALYs was universally applied. Government (33%), nonprofit (29%) and pharmaceutical (17%) funding predominated. Pharmaceutical-funded studies often employed higher WTP thresholds of US$100 000 (29%) and US$150 000 (29%). The most common intervention types were surgical (40%) and pharmaceutical (40%), whereas diseases of the choroid and retina (43%) were most frequently studied. Healthcare perspectives (17 studies) were more commonly reported than societal perspectives (6 studies).

Conclusions: US-based ophthalmology CEAs commonly use US$50 000-$100 000 WTP thresholds and a 3.0% discount rate, with higher thresholds emerging recently. Public and nonprofit funding predominates, focusing on retinal diseases and surgical or pharmaceutical interventions. Reassessing fixed WTP thresholds and incorporating societal perspectives could improve CEAs' relevance, ensuring alignment with evolving economic and healthcare landscapes.

眼科成本效益和成本效用研究中的支付意愿和参数趋势。
目的:评估眼科成本效益分析(CEA)中输入参数的频率,特别是在支付意愿(WTP)方面,并评估在美国进行的研究的长期趋势。方法和分析:对塔夫茨医学中心CEA登记处1993年至2022年期间的CEA进行了横断面分析,包括所有评估眼睛和附件疾病的研究。测量的主要结果包括WTP阈值、资金来源、干预措施类型和疾病分类的趋势。结果:82例美国cea符合纳入标准。所有的研究都评估了质量调整生命年(QALYs)的结果。最常报告的WTP阈值为5万美元(41%)和10万美元(39%),自2019年以来,9%的研究中出现了15万美元。普遍采用3.0%的成本和质量折扣。政府(33%)、非营利组织(29%)和制药公司(17%)的资助占主导地位。药物资助的研究通常采用更高的WTP阈值,分别为10万美元(29%)和15万美元(29%)。最常见的干预类型是手术(40%)和药物(40%),而脉络膜和视网膜疾病(43%)的研究最为频繁。医疗保健视角(17项研究)比社会视角(6项研究)更常被报道。结论:美国眼科cea通常使用5万美元至10万美元的WTP门槛和3.0%的贴现率,最近出现了更高的门槛。公共和非营利性资金占主导地位,主要用于视网膜疾病和手术或药物干预。重新评估固定的WTP阈值并纳入社会观点可以改善cea的相关性,确保与不断变化的经济和医疗保健格局保持一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Open Ophthalmology
BMJ Open Ophthalmology OPHTHALMOLOGY-
CiteScore
3.40
自引率
4.20%
发文量
104
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信